Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia Syndrome
Authors: JOACOB J. LOKICH
Journal: Annals of Internal Medicine (1984)

Brief Reports1 December 1984Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia SyndromeJOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.JOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-6-798 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe delivery of cancer chemotherapy by continuous infusion either for 5 days or for protracted durations has become common because of the substantial alleviation of toxicity, particularly acute gastrointestinal effects and cumulative drug effects (1). Short-term (120-hour or 5-day) infusions are commonly used for the delivery of fluorouracil (2), vinblastine (3), and doxorubicin (4). In a series of phase I and II trials of protracted infusion chemotherapy (5), we have seen an unusual dermatologic syndrome involving the palms and soles that limits the ability to continue treatment.A prodrome of dysesthesias develops in the palms and soles that is initially...References1. CARLSONSIKIC RB. Continuous infusion or bolus injection in cancer chemotherapy. Ann Inter Med. 1983;99:823-33. LinkGoogle Scholar2. SEIFERTBAKERREEDVAITKEVICIUS PHMV. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975;36:123-8. CrossrefMedlineGoogle Scholar3. YAPBLUMENSCHEINKEATINGHORTOBAGYITASHIMALOO HGMGCT. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980;64:279-83. MedlineGoogle Scholar4. LEGHABENJAMINMACKAY SRB. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1983;96:133-9. LinkGoogle Scholar5. LOKICHPERRIBOTHE JJA. Cancer chemotherapy via ambulatory infusion pump. Am J Clin Oncol. 1983;6:355-63. CrossrefMedlineGoogle Scholar6. DUNAGIN W. Clinical toxicity of chemotherapeutic agents: dermatologic toxicity. Semin Oncol. 1982;9:14-22. MedlineGoogle Scholar7. BURGDORFGILMOREGANICK WWR. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97:61-2. LinkGoogle Scholar8. DOYLEBERGBOTTINOCHABNER LCGB. Erythema and desquamation after high-dose methotrexate. Ann Intern Med. 1983;98:611-2. LinkGoogle Scholar9. VOGELZANGBOSLJOHNSONKENNEDY NGKB. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288-92. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New England Deaconess Hospital Harvard Medical School Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByReactive erythemaPerformance of capecitabine in novel combination therapies in colorectal cancerClinical and Pathologic Findings with Differential Diagnostic ListsReactive ErythemasReferences and Further ReadingManagement of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology CentersAcute Cancer Pain Syndromes in Palliative Care EmergenciesCutaneous toxicity of oral low-dose methotrexateAcute Cancer Pain Syndromes in Palliative Care EmergenciesErythrodysestesia-like skin eruption due to docetaxel with a nonimmediate positive intradermal skin test resultGestion des effets secondaires cutanés des chimiothérapies et thérapies cibléesLevofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implicationsNeoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen studyEnhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemiaAntimetabolite ReactionsThe History of Supportive OncodermatologyProphylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysisToxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplantReactive ErythemaLiposomal drug delivery systems: From concept to clinical applicationsCapecitabine induced Hand–Foot Syndrome: Report of two casesDrug-induced Nail ChangesSíndrome mão-pé induzida por quimioterapia: relato de um casoReferences and Further ReadingCutaneous adverse reactions to drugsChemotherapy-induced iatrogenic injury of skin: New drugs and new conceptsThe emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesImpact of prophylactic pyridoxine on occurrence of hand–foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancerPHARMACOKINETICS: Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in chinese patients with breast tumoursRandomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesiaPyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled StudyUnilateral hand–foot syndrome: an extraordinary side effect of capecitabineToxicity and Efficacy of 5-Fluorouracil and Capecitabine in a Patient With TYMS Gene Polymorphism: A Challenge or a Dilemma?A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving CapecitabineHand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor TherapyAn unusual presentation of hand-foot syndrome at the hidden area: The scrotum and penisHand-Foot syndrome induced by sorafenib, a multitargeted tyrosine kinase inhibitor, in a patient with advanced renal cell carcinomaAkrale Nekrosen bei metastasiertem OvarialkarzinomToxic erythema of chemotherapy: A useful clinical termEritema acral inducido por quimioterapiaHand-Foot Syndrome With Sclerodactyly-Like Changes in a Patient Treated With CapecitabineChemotherapy-induced toxic erythema under treatment with pegylated liposomal doxorubicin: No restriction to palms and solesAlopecia and Cutaneous ComplicationsChemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 CasesRisk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysisCapecitabine-induced hand–foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patientTyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney CancerTargeted therapies for kidney cancer in urologic practiceAcral Erythema with Oral Methotrexate in a ChildPalmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centrePegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)Severe palmar-plantar erythema in a patient with breast cancer receiving doxorubicin-cyclophosphamide chemotherapyReaktives ErythemHand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case ReportHand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase–Deficient Patient Treated with CapecitabinePalmar–plantar erythrodysesthesia due to docetaxel–capecitabine therapy is treated with vitamin E without dose reductionVascular Toxicity of Antineoplastic AgentsFluorouracil Plus Leucovorin Induces Submandibular Salivary Gland Enlargement in RatsPalmar-Plantar ErythrodysesthesiaReferences and Further ReadingLack of contribution of dihydrofluorouracil and α-fluoro-β-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytesHand-Foot Syndrome in Patients Treated With Capecitabine-Containing Combination ChemotherapyGrade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburnManagement of Complications of ChemotherapyManagement of hand-foot syndrome in patients treated with capecitabine (Xeloda®)Palmar-plantar erythrodysesthesiaPyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabineCutaneous Hand and Foot Toxicity Associated With Cancer ChemotherapyRate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activityClofarabine-induced Acral Erythema During the Treatment of Patients with Myelodysplasia and Acute Leukemia: Report of Two CasesSingle‐Agent Capecitabine: A Reference Treatment for Taxane‐Pretreated Metastatic Breast Cancer?Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemiaCytarabine-induced acute generalized exanthematous pustulosisPalmar-Plantar Erythrodysaesthesia Associated with an Initial Course of Bolus FluorouracilIncidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution ExperienceHand–foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbineAn EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerThe clinical pharmacology of the oral fluoropyrimidinesPegylated Liposomal Doxorubicin: Tolerability and ToxicityCaelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancerOral Fluoropyrimidines: Are They the Equivalent of Parenteral Infusional 5-Fluorouracil?Palmar-Plantar Erythrodysesthesia Syndrome Associated with Liposomal DaunorubicinChemotherapy-induced acral erythema: report of a case and immunohistochemical findingsAntineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) SyndromeCutaneous fibrosis induced by docetaxelTreatment of metastatic breast cancer with continuous infusional 5 fluorouracilPyridoxine for Hand–Foot SyndromeMucocutaneous reactions to chemotherapyRelationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogsThe Addition of Paclitaxel to Continuous Infusion 5-Fluorouracil Is an Active Regimen for Metastatic Breast CancerAcral erythema induced by chemotherapy with cisplatinCytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?Hand-foot syndrome following prolonged infusion of high doses of vinorelbineInitial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid TumorsBiomodulation of Fluorouracil in Colorectal CancerHigh Incidence of Chemotherapy-Induced Acral Erythema in Female Patients with non-Hodgkin's Lymphoma Treated with the Vacop-B RegimenFive-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patientsAcral erythema and intrahepatic 5-fluorouracil infusionPalmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?Suspected drug eruption in seven dogs during administration of flucytosineFalse Positive Tumor Markers: Elevation in Patients with Breast Cancer on FAC-type Chemotherapy and Correlation with the Development of Hand-foot SyndromeForewordA pilot study of infusional CMF (CMF-inf): Active and well tolerated in breast cancer5-Fluorouracil-associated hyperpigmentationLiposome circulation time and tumor targeting: implications for cancer chemotherapyIntermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: Relationship between plasma concentrations and clinical parametersHand-foot syndrome associated with liposome-encapsulated doxorubicin therapyThree Cases of Chemotherapy-induced Acral ErythemaInfusional Cancer Chemotherapy: Historical Evolution and Future Development at the Cancer Center of BostonDermatological Toxicity from Chemotherapy Containing 5-FluorouracilInfusional 5-fluorouracil in breast cancerDose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancerMedical Management of Colorectal CarcinomasClinical Studies of Liposome-Encapsulated DoxorubicinPharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)Protracted drug infusions in cancer treatment: An appraisal of 5-fluorouracil, doxorubicin, and platinumsCombination chemotherapy with 5-fluorouracil, folinic acid, and α-interferon producing histologic features of graft-versus-host diseaseNonsurgical management of recurrent colorectal cancerAcute mucocutaneous toxicity following high-dose hydroxyurea5-Fluorouracil: Schedule Optimization in Metastatic Colorectal CancerUnusual serpentine hyperpigmentation associated with 5-fluorouracilCytotoxic Drugs in the Treatment of Skin DiseaseContinuous systemic 5-fluorouracil infusion in refractory prostatic cancerChemotherapy-induced acral erythemaA prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A mid-atlantic oncology program studyPigmentary Effects from the Protracted Infusion of 5-FluorouracilProtracted Infusion of 5-FU with Weekly Low-Dose Cisplatin as Second-Line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed 5-FU MonotherapyToxicity of high-dose cytosine arabinoside in the treatment of advanced childhood tumors resistant to conventional therapy a pediatric oncology group studyErythema and swelling of ears after treatment with cytarabine for leukemiaFluorouracil and Palmar-Plantar ErythrodysesthesiaCharles F. Curran, PhD., James K. Luce, MD.Pyroxidine for the Palmar-Plantar Erythrodysesthesia SyndromeSvetislava J. Vukelja, MD, Fredric A. Lombardo, PharmD, William D. James, MD, Raymond B. Weiss, MDA Variant of the Chemotherapy-Associated Erythrodysesthesia Syndrome Related to High-Dose CyclophosphamideConcomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer5-fluorouracil rechallenge by protracted infusion in refractory breast cancerAcral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemiaAcral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusionsSevere dermatologic Toxocity from 5-Fluorouracil in the Presence of Seborrheic dermatitisContinuous systemic 5-fluorouracil infusion in advanced colorectal cancer: Results in 91 patientsDrug-Induced Toxicities Associated with High-Dose Cytosine Arabinoside InfusionsPainful red hands: a side-effect of leukaemia therapyPalmar-Plantar Erythrodysesthesia Syndrome Associated with Short-Term Continuous Infusion (5 Days) of 5-FluorouracilA randomized comparison of doxifluridine and fluorouracil in colorectal carcinomaHypersensitivity reactions from antineoplastic agentsContinuous 5-fluorouracil infusion in refractory carcinoma of the breastRole of chemotherapy in the treatment of colorectal carcinomaProtracted Infusional ChemotherapySystemic Infusional Chemotherapy for Liver Metastasis: An Improved Schedule for 5-FluorouracilPalmar-Plantar Skin Changes and CytarabineWIM G. PETERS, M.D., ROEL WILLEMZE, M.D.Cancer Chemotherapy and Skin ChangesNICHOLAS J. VOGELZANG, M.D., MARK J. RATAIN, M.D.Palmar-Plantar Erythrodysesthesia and CytarabineMARIA R. BAER, M.D., LLOYD E. KING, M.D., Ph. D., STEVEN N. WOLFF, M.D.Fluorouracil and the Palmar-Plantar Erythrodysesthesia SyndromeJAMES N. ATKINS, M.D. 1 December 1984Volume 101, Issue 6Page: 798-800KeywordsAdverse reactionsCancer chemotherapyChemotherapyDrug deliveryToxicity Issue Published: 1 December 1984 PDF DownloadLoading ...